NASDAQ: ORPH | Orphazyme A/S Securities Fraud Investigation Class Action
Shamis Gentile, a corporate securities fraud law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme’s September 29, 2020 initial public offering (the “IPO” or “Offering”); and/or (2) between September 29, 2020 and June 18, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 7, 2021.
If you purchased Orphazyme A/S securities and would like to join the action, please contact us immediately! Such investors are advised to contact attorney Andrew Shamis at [email protected] or 305-479-2299.
Press Release
Shamis Gentile Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline – ORPH
WHY: Shamis Gentile, a corporate securities fraud law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme’s September 29, 2020 initial public offering (the “IPO” or “Offering”); and/or (2) between September 29, 2020 and June 18, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 7, 2021.
WHAT: If you purchased Orphazyme A/S securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the KCS securities class action, please contact Andrew J. Shamis, Esq. at 305-479-2299 or email [email protected] for information on the class action.
WHAT IS THIS ABOUT: According to the lawsuit, the Offering documents and defendants during the Class Period made false and/or misleading statements and/or failed to disclose that: (1) arimoclomol was not as effective in treating Inclusion Body Myositis (“IBM”) as defendants had represented; (2) arimoclomol was not as effective in treating Amyotrophic Lateral Sclerosis (“ALS”) as defendants had represented; (3) the arimoclomol new drug application (“NDA”) for Niemann-Pick disease type C (“NPC”) was incomplete and/or required additional evidence and data to support the benefit-risk assessment of that NDA; (4) as a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the arimoclomol NDA for NPC in its present form; (5) the Company’s overall business prospects, as well as arimoclomol’s commercial prospects, were significantly overstated; and (6) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHY SHAMIS GENTILE LAW: Shamis & Gentile, P.A. is dedicated in helping misled shareholders recover damages caused by corporate fraud and other misconduct. Our securities attorneys have a wealth of knowledge and experience handling complex litigation cases and achieving significant victories and settlements for clients (over 500 million recovered and counting). In addition to our experience litigating securities cases, our attorneys have been routinely certified class counsel throughout the country where our firm has gained a reputation of one that litigates the right way and achieves large monetary settlements. Our team comes from diverse and unique backgrounds, making us equipped to bring the fight anytime and anywhere on behalf of our clients.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Andrew J. Shamis, Esq.
Shamis & Gentile, P.A.
Miami Headquarters
14 NE 1st Ave, Suite 705,
Miami, FL 33132
Tel: 305-479-2299
Fax: 786-623-0915
